Ovid Therapeutics Inc. (OVID) Stock Price & Analysis
Ovid Therapeutics Inc. (OVID) rose 2.54% to USD 2.42 as of June 10, 2026 at 08:42 UTC, according to Nexqual real-time market data.
OVID last closed at USD 2.36; the session ranged USD 2.33–2.44 on volume of 1,480,229 shares. Market capitalization is $451.67M, with a 52-week range of USD 0.27–3.11 (NCM). Source: Nexqual, June 10, 2026 at 08:42 UTC.
Key Statistics (as of June 10, 2026 at 08:42 UTC)
| Price | USD 2.42 |
|---|---|
| Change | ▲ 2.54% (up) |
| Previous Close | USD 2.36 |
| Open | USD 2.39 |
| Day Range | USD 2.33 – 2.44 |
| 52-Week Range | USD 0.27 – 3.11 |
| Volume | 1,480,229 shares |
| Market Cap | $451.67M |
| Exchange | NCM |
Technical Analysis (OVID)
Nexqual's technical model rates OVID "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:42 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.51 (neutral) |
| vs SMA50 | Below (USD 2.61) |
| MACD | -0.06 (negative) |
Analyst Ratings (OVID)
Wall Street analysts rate OVID "None" based on 9 analysts, with a mean price target of USD 5.47 (range USD 4–7), per Nexqual as of June 10, 2026 at 08:42 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 5.47 |
| High Target | USD 7 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (OVID)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.1 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.12 vs est -0.11 ▼ miss |
| 2025-12-31 | USD 0.06 vs est -0.1 ▲ beat |
| 2025-09-30 | USD -0.17 vs est -0.15 ▼ miss |
| 2025-06-30 | USD -0.06 vs est -0.15 ▲ beat |
Source: Nexqual, June 10, 2026 at 08:42 UTC.
Financials & Fundamentals (OVID)
| Total Revenue | $7.12M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -678.67% |
| Profit Margin | +0.00% |
| ROE | -18.77% |
| Debt / Equity | 6.59 |
| Current Ratio | 10.17 |
| Total Cash | $155.52M |
| Total Debt | $13.07M |
| Free Cash Flow | $-20.83M |
Source: Nexqual, June 10, 2026 at 08:42 UTC.
Financial Health Score (OVID)
Nexqual rates Ovid Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:42 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $156M cash vs $13M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$21M, burning cash |
| Efficiency | Critical — ROE -19%, ROA -19.7% |
Ownership (OVID)
| Insider Ownership | +6.98% |
|---|---|
| Institutional Ownership | +61.57% |
| Shares Outstanding | 186.64M |
| Float | 152.44M |
| Short % of Float | +6.57% |
Source: Nexqual, June 10, 2026 at 08:42 UTC.
Leadership (OVID)
Ovid Therapeutics Inc. is led by Margaret Alexander (age 44), CEO, President & Director, per Nexqual as of June 10, 2026 at 08:42 UTC.
| CEO, President & Director | Margaret Alexander (age 44) |
|---|---|
| Co-Founder & Executive Chairman | Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir (age 72) |
| Chief Scientific Officer | Zhong Zhong |
| Senior Vice President of Clinical Development | Julia Tsai (age 50) |
| Senior Vice President of Corporate Affairs & Corporate Strategy | Victoria Fort |
Major Backers & Investors (OVID)
Notable institutional backers of Ovid Therapeutics Inc. include RA Capital Management, L.P., Janus Henderson Group PLC, Affinity Asset Advisors, Llc, according to Nexqual as of June 10, 2026 at 08:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 5.74% |
| Janus Henderson Group PLC | 5.74% |
| Affinity Asset Advisors, Llc | 5.7% |
| Eventide Asset Management LLC | 5.31% |
| Federated Hermes, Inc. | 3.82% |
| Adage Capital Partners GP L.L.C. | 3.3% |
| Balyasny Asset Management LP | 2.96% |
| Adar1 Capital Management, LLC | 2.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.62% |
Source: Nexqual, June 10, 2026 at 08:42 UTC.
From Ovid Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Unmet need in epilepsy Approximately 50 million people globally live with epilepsy, including an estimated three million adults and half a million children in the United States.
- Today, we are one of the few companies that has researched and developed three distinct MoAs to target seizures and we believe we are the only company that holds a portfolio of direct activators of KCC2.
- Intellectual Property Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our current and future drug candidates, novel discoveries, product development technologies and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing upon our proprietary rights.
- We also rely on trademarks, trade secrets, copyright protection, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.
Partnerships
- We also entered into a collaboration agreement with Gensaic (the "Gensaic Collaboration Agreement") to potentially develop up to three genetic medicines for neurological indications of interest to us, harnessing Gensaic's proprietary tissue-selective intracellular delivery platform.
- Exclusive In-Licensing Agreement with AstraZeneca (2021) In December 2021, we entered into an exclusive license agreement ("AstraZeneca Exclusive License Agreement") with AstraZeneca.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc. | USD 3.85 | ▲ 0.52% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 11.17 | ▲ 0.45% |
| ASMB | Assembly Biosciences, Inc. | USD 22.72 | ▼ 0.79% |
| CLSDQ | Clearside Biomedical, Inc. | USD 0.31 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:42 UTC. This page is informational and not investment advice.